Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04412629 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib in High Grade Neuroendocrine Neoplasms
A Phase 2 study of High Grade Neuroendocrine Neoplasms, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT04412629: Active Phase 2 study of High Grade Neuroendocrine Neoplasms, sponsored by Washington University School of Medicine.
NCT04412629 is a Phase 2 study of High Grade Neuroendocrine Neoplasms that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04412629, a Phase 2 study of High Grade Neuroendocrine Neoplasms, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year. There is no extensive literature or consensus on second- or third-line options (which include FOLFOX, FOLFIRI, capecitabine and temozolomide, taxanes or immunotherapy) and there is urgent need for better regimens.
Primary Outcome
* ORR is defined as number of patients with complete response or partial response * Complete response - Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. * Partial response - At least a 30% decrease in the sum of the diameters of the longest diameter of the target lesions taking as reference the baseline sum longest diameter
Conditions Studied
Interventions
- DRUG Cabozantinib
- PROCEDURE Blood for plasma biomarkers
- PROCEDURE Tissue biopsy
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-11-24 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
What the registry record for NCT04412629 still lists
NCT04412629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with High Grade Neuroendocrine Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Cabozantinib is the first listed.
NCT04412629 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04412629 about?
NCT04412629 is a clinical study titled "Cabozantinib in High Grade Neuroendocrine Neoplasms". High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year. There is n...
What is the current status of trial NCT04412629?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2020-11-24. Estimated completion is 2026-09-30.
What conditions does trial NCT04412629 study?
This clinical trial studies the following conditions: High Grade Neuroendocrine Neoplasms.
What interventions are being tested in trial NCT04412629?
The interventions under investigation include: Cabozantinib (DRUG), Blood for plasma biomarkers (PROCEDURE), Tissue biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT04412629?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04412629 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Neuroendocrine Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04412629's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI